By Denny Jacob
Vigil Neuroscience shares more than tripled in premarket trading a day after Sanofi agreed to acquire Vigil for about $470 million.
Vigil shares were trading around $8. The stock was up 36% on the year as of Wednesday's close.
Paris-based Sanofi said Wednesday evening that it would purchase all of the clinical-stage biotechnology company's outstanding shares for an upfront payment of $8 a share. Vigil shareholders will also receive the right to an additional $2 a share in cash, payable following the first commercial sale of the in-development Alzheimer's treatment VG-3927, if achieved within a set period.
Including the possible later payout, the deal's total equity value could reach about $600 million, said Watertown, Mass.-based Vigil. The sale is expected to close in the third quarter.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 22, 2025 07:47 ET (11:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.